Background: Immune checkpoint inhibitors (ICIs) such as durvalumab improve survival in solid tumors but can rarely cause fulminant myocarditis (reported in 1% of cases, with 25%-40% mortality). Clinical overlap with coronary arte... ...

请注册登录后继续浏览